mAbTree Biologics
mAbTree Biologics AG is a Swiss- and India-based, privately-held biotech that develops proprietary fully human monoclonal antibodies and antibody-drug conjugates for oncology, immunology, and rare blood cancers, with lead asset MT0002 advancing through IND-enabling studies under a co-development partnership with Shilpa Biologicals.
- Company typePrivate
- Founded2019
- HeadquartersZwingen, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What mAbTree Biologics does
mAbTree Biologics AG is a privately-held Swiss biopharmaceutical company founded in 2019 and headquartered in Basel's Stucki Tech Park, with an additional R&D presence in Hyderabad, India. The company develops proprietary fully human monoclonal antibodies for oncology and immunology indications, anchored by an antibody-drug conjugate (ADC) platform designed to address challenging targets across cancer and autoimmune disorders. Its lead disclosed asset, MT0002, is an investigational monoclonal antibody for Essential Thrombocythemia and Polycythemia Vera (rare chronic myeloproliferative disorders) that received FDA Orphan Drug Designation in March 2026 in collaboration with co-development partner Shilpa Biologicals (Shilpa Medicare Group), and is currently advancing through IND-enabling studies toward first-in-human clinical trials.
The company's technology stack centers on antibody platform technologies capable of generating a vast repertoire of fully human, affinity-matured antibodies and modular ADCs that can be tailored to specific disease biology. The pipeline scope spans immune-oncology and broader immunology, with a stated mission to deliver first-in-class or best-in-class antibody therapies to diseases with high unmet medical need, including rare hematological malignancies and solid tumors.
mAbTree is pre-commercial and generates no product revenue. Its business model is partnership- and licensing-oriented: the company enables access to third-party technologies and its own antibody assets via strategic alliances, licensing agreements, and co-development arrangements with pharmaceutical and biotech partners, with future commercialization contemplated through those licensing/royalty pathways or direct sales post-approval. Customer end-markets are segmented into oncology patients, autoimmune disease patients, and rare blood cancer patients, but with no products on market today the company currently has no paying customers and no disclosed revenue.
mAbTree Biologics firmographics
Firmographics- Name
- mAbTree Biologics
- Legal name
- mAbTree Biologics AG
- Website
- https://mabtree.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- mAbTree Biologics AG is a Swiss- and India-based, privately-held biotech that develops proprietary fully human monoclonal antibodies and antibody-drug conjugates for oncology, immunology, and rare blood cancers, with lead asset MT0002 advancing through IND-enabling studies under a co-development partnership with Shilpa Biologicals.
- Ownership category
- akta.pro rank
mAbTree Biologics industry classification
Industry- Product category
- Therapeutic Antibodies
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where mAbTree Biologics is headquartered
LocationHeadquarters
- HQ city
- Zwingen
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
mAbTree Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Biopharmaceutical Product Sales: mAbTree Biologics is developing a pipeline of antibody therapeutics for cancer and autoimmune diseases. Upon regulatory approval, the company plans to commercialize these products, likely through licensing agreements, co-development partnerships, or direct sales.
- Partnership and Licensing Revenue: The company generates value through partnerships with pharmaceutical and biotech companies, enabling access to its technology platforms and pipeline assets through licensing, co-development, and strategic alliance agreements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
mAbTree Biologics product offering
Product offeringCore offering
mAbTree Biologics develops proprietary fully human affinity-matured monoclonal antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer and autoimmune diseases. The company's lead clinical-stage asset is MT0002, an investigational monoclonal antibody targeting Essential Thrombocythemia and Polycythemia Vera that has received FDA Orphan Drug Designation. The company operates a modular ADC platform enabling the creation of tailored therapeutics against challenging disease targets.
Product overview
mAbTree Biologics is a biopharmaceutical company developing proprietary human monoclonal antibody therapies for oncology and immunology. The company's core product portfolio includes MT0002, an investigational monoclonal antibody targeting rare blood cancers (Essential Thrombocythemia and Polycythemia Vera) that received FDA Orphan Drug Designation. The company operates an antibody-drug conjugate platform that generates fully human affinity-matured antibodies and antibody-drug conjugates for cancer and autoimmune disease treatment. The company is building a pipeline of assets in immune diseases and immune oncology therapeutic spaces.
Differentiator
Problem solved
Functional benefit
Products and services
- MT0002 Investigational monoclonal antibody therapy targeting Essential Thrombocythemia and Polycythemia Vera (rare chronic myeloproliferative disorders). Co-developed with Shilpa Biologicals under FDA Orphan Drug Designation, providing up to seven years of market exclusivity upon approval along with development support and tax credits.
- Antibody-Drug Conjugate (ADC) Platform Proprietary technology platform that generates a vast repertoire of fully human affinity-matured antibodies and antibody-drug conjugates against challenging disease targets. The modular ADC architecture enables the creation of unique and tailored therapeutics for cancer and autoimmune disorders, designed to overcome cancer immune tolerance and escape.
Quantifiable outcome
- Orphan Drug Designation grants regulatory and commercial incentives including development support, tax credits, and up to seven years of market exclusivity upon approval
Companies that use mAbTree Biologics
Customer profileSegments3 records
Ideal customer profiles2 records
mAbTree Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
mAbTree Biologics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Shilpa Biologicals (Shilpa Medicare Group)coreShilpa Biologicals (part of Shilpa Medicare Group) and mAbTree Biologics AG are co-developing an investigational monoclonal antibody targeting Essential Thrombocythemia and Polycythemia Vera. The partnership received FDA Orphan Drug Designation, providing regulatory and commercial incentives including development support, tax credits, and up to seven years of market exclusivity upon approval. The companies are advancing the program through IND-enabling studies with the objective of initiating first-in-human clinical trials.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
mAbTree Biologics competitors and assessment
Company assessmentDirect peers
- ADC Therapeutics: Pure-play ADC specialist developing antibody-drug conjugates for hematological cancers and solid tumors — directly comparable to mAbTree's modular ADC platform and hematology indication focus.
- Heidelberg Pharma: German ADC company developing targeted cancer therapeutics using proprietary payload chemistry and linker technology — a comparable European small-cap ADC platform play with oncology focus.
- Innovent Biologics: China-based biopharmaceutical company developing monoclonal antibodies and ADCs for oncology and autoimmune disease with a strong cost-efficient manufacturing footprint — comparable dual oncology/autoimmune antibody focus with emerging-market reach.
- Genmab: Antibody innovation company with proprietary mAb discovery/engineering platforms (e.g., DuoBody, HexaBody) and a deep pipeline of partnered programs — a comparable platform-based mAb business model with both proprietary and out-licensed assets.
- Argenx: Clinical-stage immunology biotech built around a proprietary antibody discovery platform (Simple Antibody) that generates differentiated human mAbs for autoimmune disease — directly comparable to mAbTree's human antibody platform and autoimmune focus.
- MacroGenics: Clinical-stage biotech using proprietary antibody platforms (DART, TRIDENT) to develop immuno-oncology and autoimmune mAbs — a comparable platform-to-pipeline antibody company targeting overlapping oncology and autoimmune indications.
- MorphoSys: Antibody discovery company with proprietary HuCAL platform generating human mAbs for oncology and inflammatory disease; now part of Novartis — illustrates the partnership-heavy commercial model mAbTree is pursuing.
Broad incumbents
- Daiichi Sankyo: Japanese major pharma that pioneered the modern ADC modality (with AstraZeneca-partnered Enhertu) and operates a large proprietary mAb/ADC pipeline — a broad incumbent defining competitive benchmarks in the ADC space mAbTree is targeting.
- WuXi Biologics: Global leading open-access biologics technology platform and CDMO providing end-to-end mAb discovery, development, and manufacturing services — a broad incumbent that both competes with and enables smaller antibody developers.
Emerging players
- Zymeworks: Clinical-stage biotech developing multifunctional antibody platforms including bispecifics and ADCs — an emerging platform peer with overlapping antibody engineering capabilities but broader technology scope.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights6 records
Customer concentration
mAbTree Biologics social profiles
Digital presencemAbTree Biologics compliance and trust
Trust signalCompliance2 records
mAbTree Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
mAbTree Biologics leadership team
Management profileNumber of profiles
Profiles11 records
mAbTree Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
mAbTree Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about mAbTree Biologics
What does mAbTree Biologics do?
mAbTree Biologics develops proprietary fully human affinity-matured monoclonal antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer and autoimmune diseases. The company's lead clinical-stage asset is MT0002, an investigational monoclonal antibody targeting Essential Thrombocythemia and Polycythemia Vera that has received FDA Orphan Drug Designation. The company operates a modular ADC platform enabling the creation of tailored therapeutics against challenging disease targets.
Is mAbTree Biologics a public or private company?
mAbTree Biologics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was mAbTree Biologics founded?
mAbTree Biologics was founded in 2019. It employs 11 to 50 people.
Where is mAbTree Biologics based?
mAbTree Biologics is headquartered in Zwingen, Switzerland, in the Europe region.
How does mAbTree Biologics make money?
Two revenue lines are on record. Biopharmaceutical Product Sales are the primary driver. The others are partnership and Licensing Revenue.
Who are mAbTree Biologics's main competitors?
Direct peers on record are ADC Therapeutics, Heidelberg Pharma, Innovent Biologics, Genmab, Argenx, MacroGenics and MorphoSys. Broad incumbents are Daiichi Sankyo and WuXi Biologics. Zymeworks is listed as an emerging player.
Does mAbTree Biologics have an API?
No public API is recorded for mAbTree Biologics.
What industry is mAbTree Biologics in?
mAbTree Biologics's product category is Therapeutic Antibodies. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.